Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03836352
Title Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ImmunoVaccine Technologies, Inc. (IMV Inc.)

lung non-small cell carcinoma

ovary epithelial cancer

Advanced Solid Tumor

peritoneum cancer

hepatocellular carcinoma

fallopian tube cancer

transitional cell carcinoma


DPX-Survivac + Pembrolizumab

Cyclophosphamide + DPX-Survivac + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.